

LISTING OF THE CLAIMS

1. (Original) A method for treating proliferative skin diseases comprising the administration of an effective amount of tazarotene and an effective amount of a corticosteroid.
2. (Previously amended) The method of claim 1 wherein said corticosteroid is selected from the group consisting of fluocinolone acetonide, mometasone furoate, fluocinonide, diflorasone diacetate, fluticasone propionate, betamethasone dipropionate, clobetasol propionate, and betamethasone valerate.
3. (Original) The method of claim 1 wherein tazarotene is applied as a 0.1% gel.
4. (Previously amended) The method of claim 1 wherein said corticosteroid is selected from the group consisting of mometasone furoate, fluocinonide, alclometasone dipropionate, and betamethasone valerate.
5. (Previously amended) The method of claim 4 wherein said corticosteroid is selected from the group consisting of alclometasone dipropionate, and betamethasone valerate.
6. (Original) A method for treating psoriasis in a human subject by topically applying to the psoriatic skin of said subject an effective amount of tazarotene and an effective amount of a corticosteroid.
7. (Original) The method of claim 6 wherein tazarotene is applied as a 0.1% gel.
8. (Original) The method of claim 7 wherein said corticosteroid is a cream.
9. (Previously amended) The method of claim 8 wherein said corticosteroid is selected from the group consisting of mometasone furoate, fluocinonide, alclometasone dipropionate, and betamethasone valerate.
10. (Previously amended) The method of claim 9 wherein said corticosteroid is selected from the group consisting of alclometasone dipropionate, and betamethasone valerate.
11. (Original) The method of claim 6 wherein tazarotene is administered once daily in the evening and the corticosteroid is administered once daily in the morning.